| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
ERα/ERβ
|
|---|---|
| References |
[1]. RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models. Anticancer Drugs. 2015 Oct;26(9):948-56.
|
| Additional Infomation |
Drugs that inhibit estrogen production, such as aromatase inhibitors, or drugs that directly block estrogen receptor (ER) activity, such as selective estrogen receptor modulators and selective estrogen receptor degraders, are routinely used to treat ER-positive breast cancer. However, despite the often effective initial treatment with these drugs, many women eventually experience recurrence and develop drug-resistant breast cancer. To overcome some of the challenges of current endocrine therapy and combat the development of resistance, there is an urgent need to develop more durable and effective ER-targeted therapies. This article describes and characterizes a novel, orally bioavailable, small-molecule selective estrogen receptor degrader, RAD1901, and evaluates its potential application in breast cancer treatment. RAD1901 selectively binds to and degrades ER, acting as a potent antagonist of ER-positive breast cancer cell proliferation. Importantly, RAD1901 exhibits significant tumor growth inhibition in the MCF-7 xenograft model. In the intracranial MCF-7 model, animals treated with RAD1901 had a longer survival time than those in the control group and the fulvestrant group, suggesting that RAD1901 may have potential therapeutic value for ER-positive breast cancer that has metastasized to the brain. In addition, RAD1901 can reduce bone loss caused by oophorectomy and inhibit the uterine-promoting effect of E2, suggesting that it may act as an agonist in bone and an antagonist in breast and uterine tissues. Currently, RAD1901 is being studied in clinical trials in postmenopausal patients with ER-positive advanced breast cancer. [1]
|
| Molecular Formula |
C30H40CL2N2O2
|
|---|---|
| Molecular Weight |
531.5568
|
| Exact Mass |
530.246
|
| Elemental Analysis |
C, 78.56; H, 8.35; N, 6.11; O, 6.98
|
| CAS # |
2309762-30-7
|
| Related CAS # |
Elacestrant;722533-56-4;Elacestrant dihydrochloride;1349723-93-8;Elacestrant (S enantiomer);2309762-29-4
|
| PubChem CID |
127020970
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
36
|
| Complexity |
578
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
Cl[H].Cl[H].O([H])C1C([H])=C([H])C2=C(C=1[H])C([H])([H])C([H])([H])[C@]([H])(C1C([H])=C([H])C(=C([H])C=1N(C([H])([H])C([H])([H])[H])C([H])([H])C1C([H])=C([H])C(C([H])([H])C([H])([H])N([H])C([H])([H])C([H])([H])[H])=C([H])C=1[H])OC([H])([H])[H])C2([H])[H]
|
| InChi Key |
XGFHYCAZOCBCRQ-ROPHLPQBSA-N
|
| InChi Code |
InChI=1S/C30H38N2O2.2ClH/c1-4-31-17-16-22-6-8-23(9-7-22)21-32(5-2)30-20-28(34-3)14-15-29(30)26-11-10-25-19-27(33)13-12-24(25)18-26;;/h6-9,12-15,19-20,26,31,33H,4-5,10-11,16-18,21H2,1-3H3;2*1H/t26-;;/m0../s1
|
| Chemical Name |
(6S)-6-[2-[ethyl-[[4-[2-(ethylamino)ethyl]phenyl]methyl]amino]-4-methoxyphenyl]-5,6,7,8-tetrahydronaphthalen-2-ol;dihydrochloride
|
| Synonyms |
Elacestrant S enantiomer dihydrochloride; 2309762-30-7; Elacestrant (S enantiomer dihydrochloride); (6S)-6-[2-[ethyl-[[4-[2-(ethylamino)ethyl]phenyl]methyl]amino]-4-methoxyphenyl]-5,6,7,8-tetrahydronaphthalen-2-ol;dihydrochloride; RAD1901 S enantiomer dihydrochloride;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8813 mL | 9.4063 mL | 18.8126 mL | |
| 5 mM | 0.3763 mL | 1.8813 mL | 3.7625 mL | |
| 10 mM | 0.1881 mL | 0.9406 mL | 1.8813 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
